Merlin, a multi-suppressor from cell membrane to the nucleus

FEBS Letters

Volumn 586, Issue 10, 2012, Pages 1403-1408

  Zhou, Lu ^a   Hanemann, C Oliver ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

DCAF1; Integrin; Merlin; NF2; RTK

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CATENIN; BORTEZOMIB; CELL PROTEIN; FOCAL ADHESION KINASE; INTEGRIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MERLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME INHIBITOR; PROTEIN CRL4 DCAF1; PROTEIN HIPPO; PROTEIN KINASE B; PROTEIN PAK; PROTEIN TYROSINE KINASE; RAC PROTEIN; RAF PROTEIN; RAS PROTEIN; SORAFENIB; TYROSINE KINASE RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WNT PROTEIN;

ACOUSTIC NEURINOMA; ANTINEOPLASTIC ACTIVITY; CELL CYCLE ARREST; CELL MEMBRANE; CELL NUCLEUS; COLON CANCER; CONTACT INHIBITION; DRUG TARGETING; GENE; GROWTH INHIBITION; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INHIBITION; MOLECULAR INTERACTION; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 2 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RADIOSURGERY; REVIEW;

ANIMALS; CELL MEMBRANE; CELL NUCLEUS; GENE EXPRESSION PROFILING; HUMANS; INTEGRINS; MICE; NEUROFIBROMIN 2; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84861185141     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2012.03.016     Document Type: Review

References (85)

1. G.A. Rouleau Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 Nature 363 1993 515 521 (Pubitemid 23186636)
2. J.A. Trofatter A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor Cell 72 1993 791 800 (Pubitemid 23093886)
3. C. Bianchi Malignant mesothelioma: various key aspects Ann. Ist Super Sanita 30 1994 253 256
4. H. Chen Moesin-ezrin-radixin-like protein (merlin) mediates protein interacting with the carboxyl terminus-1 (PICT-1)-induced growth inhibition of glioblastoma cells in the nucleus Int. J. Biochem. Cell Biol. 43 2011 545 555
5. Y.K. Lau, L.B. Murray, S.S. Houshmandi, Y. Xu, D.H. Gutmann, and Q. Yu Merlin is a potent inhibitor of glioma growth Cancer Res. 68 2008 5733 5742
6. K.A. Morrow, S. Das, B.J. Metge, K. Ye, M.S. Mulekar, J.A. Tucker, R.S. Samant, and L.A. Shevde Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation J. Biol. Chem. 286 2011 40376 40385
7. H.M. Xu, and D.H. Gutmann Merlin differentially associates with the microtubule and actin cytoskeleton J. Neurosci. Res. 51 1998 403 415 (Pubitemid 28078471)
8. A.I. McClatchey, and R.G. Fehon Merlin and the ERM proteins-regulators of receptor distribution and signaling at the cell cortex Trends Cell Biol. 19 2009 198 206
9. W. Li Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus Cell 140 2010 477 490
10. V.J. Obremski, A.M. Hall, and C. Fernandez-Valle Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells J. Neurobiol. 37 1998 487 501 (Pubitemid 28549213)
11. C. Flaiz, S. Ammoun, A. Biebl, and C.O. Hanemann Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma Brain Pathol. 19 2009 27 38
12. T. Utermark, K. Kaempchen, and C.O. Hanemann Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins Brain Pathol. 13 2003 352 363 (Pubitemid 36975825)
13. C.O. Hanemann, B. Bartelt-Kirbach, R. Diebold, K. Kampchen, S. Langmesser, and T. Utermark Differential gene expression between human schwannoma and control Schwann cells Neuropathol. Appl. Neurobiol. 32 2006 605 614 (Pubitemid 44684646)
14. Ammoun, S., Schmid, M.C., Zhou, L., Ristic, N., Ercolano, E., Hilton, D.A., Perks, C.M. and Hanemann, C.O. (2011). Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. Oncogene, http://dx.doi.org/10.1038/onc.2011.357.
15. M.A. Lopez-Lago, T. Okada, M.M. Murillo, N. Socci, and F.G. Giancotti Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling Mol. Cell Biol. 29 2009 4235 4249
16. R. Rong, E.I. Surace, C.A. Haipek, D.H. Gutmann, and K. Ye Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression Oncogene 23 2004 8447 8454 (Pubitemid 39540795)
17. G.H. Xiao, A. Beeser, J. Chernoff, and J.R. Testa P21-activated kinase links Rac/Cdc42 signaling to merlin J. Biol. Chem. 277 2002 883 886 (Pubitemid 34968830)
18. C. Flaiz, J. Chernoff, S. Ammoun, J.R. Peterson, and C.O. Hanemann PAK kinase regulates Rac GTPase and is a potential target in human schwannomas Exp. Neurol. 218 2009 137 144
19. J.L. Kissil, E.W. Wilker, K.C. Johnson, M.S. Eckman, M.B. Yaffe, and T. Jacks Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1 Mol. Cell 12 2003 841 849 (Pubitemid 37352778)
20. H. Morrison, T. Sperka, J. Manent, M. Giovannini, H. Ponta, and P. Herrlich Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac Cancer Res. 67 2007 520 527 (Pubitemid 46192188)
21. T. Okada, M. Lopez-Lago, and F.G. Giancotti Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane J. Cell Biol. 171 2005 361 371 (Pubitemid 41540027)
22. R.J. Shaw The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling Dev. Cell 1 2001 63 72 (Pubitemid 33586069)
23. C. Flaiz, K. Kaempchen, C. Matthies, and C.O. Hanemann Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas J. Neuropathol. Exp. Neurol. 66 2007 608 616 (Pubitemid 47051706)
24. K. Kaempchen, K. Mielke, T. Utermark, S. Langmesser, and C.O. Hanemann Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells Hum. Mol. Genet. 12 2003 1211 1221 (Pubitemid 36722601)
25. S.K. Mitra, D.A. Hanson, and D.D. Schlaepfer Focal adhesion kinase: in command and control of cell motility Nat. Rev. Mol. Cell Biol. 6 2005 56 68 (Pubitemid 40064899)
26. W.G. Cance, J.E. Harris, M.V. Iacocca, E. Roche, X. Yang, J. Chang, S. Simkins, and L. Xu Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes Clin. Cancer Res. 6 2000 2417 2423 (Pubitemid 30399210)
27. V. Gabarra-Niecko, M.D. Schaller, and J.M. Dunty FAK regulates biological processes important for the pathogenesis of cancer Cancer Metastasis Rev. 22 2003 359 374 (Pubitemid 36791892)
28. A.L. Lark High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype Mod. Pathol. 18 2005 1289 1294 (Pubitemid 41348647)
29. L.V. Owens, L. Xu, R.J. Craven, G.A. Dent, T.M. Weiner, L. Kornberg, E.T. Liu, and W.G. Cance Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors Cancer Res. 55 1995 2752 2755
30. J. Zhao, and J.L. Guan Signal transduction by focal adhesion kinase in cancer Cancer Metastasis Rev. 28 2009 35 49
31. S.K. Mitra, and D.D. Schlaepfer Integrin-regulated FAK-Src signaling in normal and cancer cells Curr. Opin. Cell Biol. 18 2006 516 523 (Pubitemid 44332916)
32. V. Bolos, J.M. Gasent, S. Lopez-Tarruella, and E. Grande The dual kinase complex FAK-Src as a promising therapeutic target in cancer Onco Targets Ther. 3 2010 83 97
33. S. Ammoun, C. Flaiz, N. Ristic, J. Schuldt, and C.O. Hanemann Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma Cancer Res. 68 2008 5236 5245
34. P.I. Poulikakos, G.H. Xiao, R. Gallagher, S. Jablonski, S.C. Jhanwar, and J.R. Testa Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK Oncogene 25 2006 5960 5968 (Pubitemid 44477290)
35. S.S. Houshmandi, R.J. Emnett, M. Giovannini, and D.H. Gutmann The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner Mol. Cell Biol. 29 2009 1472 1486
36. M.F. James, S. Han, C. Polizzano, S.R. Plotkin, B.D. Manning, A.O. Stemmer-Rachamimov, J.F. Gusella, and V. Ramesh NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth Mol. Cell Biol. 29 2009 4250 4261
37. R.K. Assoian, and M.A. Schwartz Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression Curr. Opin. Genet. Dev. 11 2001 48 53 (Pubitemid 32119277)
38. W. Guo, and F.G. Giancotti Integrin signalling during tumour progression Nat. Rev. Mol. Cell Biol. 5 2004 816 826 (Pubitemid 39336275)
39. M. Curto, B.K. Cole, D. Lallemand, C.H. Liu, and A.I. McClatchey Contact-dependent inhibition of EGFR signaling by Nf2/Merlin J. Cell Biol. 177 2007 893 903 (Pubitemid 46873094)
40. S. Ammoun, and C.O. Hanemann Emerging therapeutic targets in schwannomas and other merlin-deficient tumors Nat. Rev. Neurol. 7 2011 392 399
41. D. Lallemand Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas Oncogene 28 2009 854 865
42. J.T. Fraenzer, H. Pan, L. Minimo Jr., G.M. Smith, D. Knauer, and G. Hung Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation Int. J. Oncol. 23 2003 1493 1500
43. D.R. Scoles, D.P. Huynh, M.S. Chen, S.P. Burke, D.H. Gutmann, and S.M. Pulst The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate Hum. Mol. Genet. 9 2000 1567 1574 (Pubitemid 30426993)
44. V. Baron, and M. Schwartz Cell adhesion regulates ubiquitin-mediated degradation of the platelet-derived growth factor receptor beta J. Biol. Chem. 275 2000 39318 39323 (Pubitemid 32058953)
45. R. Rong, X. Tang, D.H. Gutmann, and K. Ye Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L Proc. Natl. Acad. Sci. USA 101 2004 18200 18205 (Pubitemid 40054097)
46. C.H. Streuli, and N. Akhtar Signal co-operation between integrins and other receptor systems Biochem. J. 418 2009 491 506
47. C. Flaiz, T. Utermark, D.B. Parkinson, A. Poetsch, and C.O. Hanemann Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells Glia 56 2008 506 515
48. H. Morrison The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44 Genes Dev. 15 2001 968 980 (Pubitemid 32323547)
49. D. Lallemand, M. Curto, I. Saotome, M. Giovannini, and A.I. McClatchey NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions Genes Dev. 17 2003 1090 1100 (Pubitemid 36534984)
50. E.E. Bosco, Y. Nakai, R.F. Hennigan, N. Ratner, and Y. Zheng NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation Oncogene 29 2010 2540 2549
51. L. Zhou, E. Ercolano, S. Ammoun, M.C. Schmid, M.A. Barczyk, and C.O. Hanemann Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/beta-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways Neoplasia 13 2011 1101 1112
52. W. Li, and F.G. Giancotti Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1) Cell Cycle 9 2010 4433 4436
53. J. Lee, and P. Zhou DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase Mol. Cell 26 2007 775 780 (Pubitemid 46921011)
54. L.A. Higa, and H. Zhang Stealing the spotlight: CUL4-DDB1 ubiquitin ligase docks WD40-repeat proteins to destroy Cell Div. 2 2007 5
55. L.J. Saucedo, and B.A. Edgar Filling out the Hippo pathway Nat. Rev. Mol. Cell Biol. 8 2007 613 621 (Pubitemid 47106618)
56. B. Zhao, K. Tumaneng, and K.L. Guan The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal Nat. Cell Biol. 13 2011 877 883
57. A.A. Steinhardt, M.F. Gayyed, A.P. Klein, J. Dong, A. Maitra, D. Pan, E.A. Montgomery, and R.A. Anders Expression of Yes-associated protein in common solid tumors Hum. Pathol. 39 2008 1582 1589
58. L. Zender Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach Cell 125 2006 1253 1267 (Pubitemid 43929093)
59. E. Cho, Y. Feng, C. Rauskolb, S. Maitra, R. Fehon, and K.D. Irvine Delineation of a Fat tumor suppressor pathway Nat. Genet. 38 2006 1142 1150 (Pubitemid 44470359)
60. F. Hamaratoglu, M. Willecke, M. Kango-Singh, R. Nolo, E. Hyun, C. Tao, H. Jafar-Nejad, and G. Halder The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis Nat. Cell Biol. 8 2006 27 36 (Pubitemid 43064794)
61. K. Striedinger, S.R. VandenBerg, G.S. Baia, M.W. McDermott, D.H. Gutmann, and A. Lal The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP Neoplasia 10 2008 1204 1212
62. T. Yokoyama YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation Carcinogenesis 29 2008 2139 2146
63. J. Yu, Y. Zheng, J. Dong, S. Klusza, W.M. Deng, and D. Pan Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded Dev. Cell 18 2010 288 299
64. M. Kalamarides Neurofibromatosis 2011: a report of the Children's Tumor Foundation Annual Meeting Acta Neuropathol. 123 3 2012 369 380
65. Z.K. Ahmad, C.M. Brown, R.A. Cueva, A.F. Ryan, and J.K. Doherty ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas Otol. Neurotol. 32 2011 841 847
66. S. Ammoun, C.H. Cunliffe, J.C. Allen, L. Chiriboga, F.G. Giancotti, D. Zagzag, C.O. Hanemann, and M.A. Karajannis ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma Neuro. Oncol. 12 2010 834 843
67. M.L. Bush, S.S. Burns, J. Oblinger, S. Davletova, L.S. Chang, D.B. Welling, and A. Jacob Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors Otol. Neurotol. 33 2012 244 257
68. S. Ammoun, M.C. Schmid, J. Triner, P. Manley, and C.O. Hanemann Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2 Neuro. Oncol. 13 2011 759 766
69. S.R. Plotkin Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 N. Engl. J. Med. 361 2009 358 367
70. S.M. Maira Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 7 2008 1851 1863
71. S.R. Ande, J. Chen, and S. Maddika The ubiquitin pathway: an emerging drug target in cancer therapy Eur. J. Pharmacol. 625 2009 199 205
72. D. Hoeller, and I. Dikic Targeting the ubiquitin system in cancer therapy Nature 458 2009 438 444
73. Y. Yang Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics Cancer Res. 67 2007 9472 9481 (Pubitemid 47535937)
74. R. Honda, H. Tanaka, and H. Yasuda Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 FEBS Lett. 420 1997 25 27 (Pubitemid 28037193)
75. C.L. Brooks, and W. Gu P53 regulation by ubiquitin FEBS Lett. 585 2011 2803 2809
76. A.G. Eldridge, and T. O'Brien Therapeutic strategies within the ubiquitin proteasome system Cell Death Differ. 17 2010 4 13
77. J. Ahn, T. Vu, Z. Novince, J. Guerrero-Santoro, V. Rapic-Otrin, and A.M. Gronenborn HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation J. Biol. Chem. 285 2010 37333 37341
78. E.B. Traenckner, S. Wilk, and P.A. Baeuerle A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B EMBO J. 13 1994 5433 5441 (Pubitemid 24351822)
79. R.Z. Orlowski, and D.J. Kuhn Proteasome inhibitors in cancer therapy: lessons from the first decade Clin. Cancer Res. 14 2008 1649 1657 (Pubitemid 351469448)
80. T.A. Soucy An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer Nature 458 2009 732 736
81. J.E. Brownell Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ Mol. Cell 37 2010 102 111
82. M.A. Milhollen MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma Blood 116 2010 1515 1523
83. T.A. Soucy, L.R. Dick, P.G. Smith, M.A. Milhollen, and J.E. Brownell The NEDD8 conjugation pathway and its relevance in cancer biology and therapy Genes Cancer 1 2010 708 716
84. C.M. McCall, P.L. Miliani de Marval, P.D. Chastain 2nd, S.C. Jackson, Y.J. He, Y. Kotake, J.G. Cook, and Y. Xiong Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development Mol. Cell Biol. 28 2008 5621 5633
85. D. Wei Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor Cancer Res. 72 2012 282 293